Reuters logo
1 个月内
BRIEF-Seattle Genetics submits supplemental biologics license application to fda for Adcetris
2017年6月20日 / 中午12点20分 / 1 个月内

BRIEF-Seattle Genetics submits supplemental biologics license application to fda for Adcetris

1 分钟阅读

June 20 (Reuters) - Seattle Genetics Inc:

* Seattle Genetics submits supplemental biologics license application to FDA for Adcetris® (brentuximab vedotin) in cutaneous t-cell lymphoma

* Seattle Genetics Inc - adcetris is currently not approved for treatment of ctcl

* Seattle Genetics- trial achieved primary endpoint with adcetris treatment arm demonstrating highly statistically significant improvement for adcetris

* Seattle Genetics- bla based on trial results from phase 3 alcanza,phase 2 investigator-sponsored studies in cutaneous t-cell lymphoma for adcetris Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below